Introduction
The PLAC Ⅱ (Pravastatin, Lipids, and Atheroscle-rosis in the Carotids) study in 1995 was the first trial to demonstrate pravastatin's role in reducing common carotid artery intima-media thickness (CCA-IMT) in hypercholesterolemic patients with coronary heart disease 1) . Several other randomized controlled trials that followed further demonstrated statins' beneficial effect on progression of CCA-IMT in a wide range of individuals [2] [3] [4] [5] [6] . However, other trials soon emerged showing conflicting results [7] [8] [9] [10] [11] [12] , including the Regression Growth Evaluation Statin Study (REGRESS), which Yubei Huang and Weiqin Li contributed equally to this work.
at the end of the trial; and (3) follow-up was at least 6 months.
Data Sources and Searching Strategy
To identify relevant trials, searches in the following 3 databases (from inception to October 25, 2011), MEDLINE (OVID), EMBASE, and Cochrane Central Register of Controlled Trials, were performed by two reviewers working independently and in parallel. References of related published major systematic reviews on the subject were also obtained and reviewed. Finally, the authors of possibly relevant trials were contacted when more information or clarification was needed.
Searches were not limited by language. Studies were obtained using the two groups of key terms as Medical Subject Headings in the searching strategies: 1) HMG-COA reductase inhibitor, hydroxymethylglutaryl-CoA reductase inhibitors, atorvastatin, fluvastatin, lovastatin, pravastatin, rosuvastatin and simvastatin; 2) carotid artery plaque, carotid artery diseases, carotid artery injuries, and carotid stenosis. (for details refer to Appendix 1).
Study Selection
Two review authors (Huang and Li) working independently and in parallel, scanned related abstracts and obtained the full text reports of studies when the abstract indicated or suggested the study was a RCT evaluating statin therapy based on the outcome of interest. After obtaining full reports of the candidate trials (either in full peer-reviewed publications or press articles), the same review authors independently assessed the eligibility of the studies for inclusion in the review. Any disagreement in study selection was adjudicated by a third reviewer (Wu) .
Data Collection
The same two review authors extracted data from the eligible trials independently using standardized forms. Information about the statin, the type of intervention being tested, the baseline characteristics of the population being studied [age, sex, body mass index (BMI), current smoking, hypertension, history of myocardial infarction (MI), history of diabetes mellitus (DM)], the baseline lipid levels [total cholesterol (TC), low density lipoprotein cholesterol (LDL-C), high density lipoprotein cholesterol (HDL-C), and triglycerides (TG)], the measurement and mean CCA-IMT in each arm, and the length of follow-up were collected.
When studies did not report baseline characteristics for the whole population, we re-calculated the concluded that pravastatin had no effect on the far wall of CCA-IMT in male patients with coronary artery disease 13) . Although previous systematic reviews have explored the effects of statin therapy on the progression of CCA-IMT to make sense of the existing evidence, several critical concerns in the study designs of these reviews likely biased the pooled results. Amarenco (2004) and Kang (2004) identified only 9 and 10 trials, respectively 14, 15) . The latest review (2010) included 11 trials 16) , but a few large-scale trials, such as the FAST (Fukuoka Atherosclerosis Trial) 6) , HYRIM (Hypertension High Risk Management trial) 17) , LiSA (Lescol in Severe Atherosclerosis trial) 18) , and PRE-VEND IT (Prevention of REnal and Vascular ENdstage Disease Intervention Trial), were not included 8) .
Each of these three reviews also included at least 2 of the following 4 trials, ARBITER (ARterial Biology for the Investigation of the Treatment Effects of Reducing cholesterol), ASAP (Atorvastatin versus Simvastatin on Atherosclerosis Progression), Van and VYCTOR (The VYtorin on Carotid intima-media Thickness and Overall arterial Rigidity), which compared the effects of different statins but not statins with a placebo and/ or usual care [19] [20] [21] [22] . These selection choices undoubtedly caused heterogeneity among the included trials and biased the pooled results. Furthermore, none of the three reviews explored the effect of statin therapy on the progression of CCA-IMT in different subgroups with respect to the demographic characteristics of the participants, the duration of follow-up, and the type and dose of statin used.
In order to update the current evidence on statin therapy and its effect on CCA-IMT progression, we undertook this systematic review and meta-analysis to help resolve these uncertainties and further define statins' effect on CCA-IMT.
Method
We conducted this systematic review according to the PRISMA statement 23) .
Eligibility Criteria
All potential randomized controlled trials (RCTs) and cluster-RCTs were considered for review, excluding quasi-RCTs (trials with little or no randomization), and trials comparing different statins or different doses of the same statin on CCA-IMT. Only eligible RCTs fulfilling the following criteria were included in this systematic review: (1) the RCT compares a statin with either a placebo or usual care (including diet control); (2) the RCT provides mean CCA-IMT plots of the WMD versus its standard error 25, 26) . The I 2 statistic was calculated as a measure of the proportion of the overall variation that is attributable to between-study heterogeneity 27, 28) . Because cerivastatin was withdrawn from the market in 2001 due to reports of fatal rhabdomyolysis 29) , sensitivity analysis excluding the trials evaluating the effect of cerivastatin was conducted.
Pre-specified subgroup meta-analysis was used to explore potential sources of between-study heterogeneity according to the type of statin, patient's condition (primary prevention or secondary prevention), study quality (JADAD scored as low or high), duration of follow-up (≥ 2 years or ＜2 years), mean age of participants (≥ 60 years or ＜60 years) and gender proportion (male ≥ female or male ＜ female). Univariate meta-regression analysis was used to explore the dose response relationship between the change in CCA-IMT and baseline level of CCA-IMT, as well as the change in CCA-IMT and between-group differences in lipid level decrease 30, 31) . All statistical analyses were performed with STATA (version 12.0). arithmetical means. Any disagreement in data collection was adjudicated by the same third reviewer (Wu) .
Jadad scoring was used to assess the methodological quality of the studies 24) . Based on this system, studies are scored according to the presence of three key methodological features: randomization, blinding, and withdrawals/dropouts, with scores ranging from 0-5. Studies with a Jadad score of 4 or 5 are considered high quality, while those receiving a score of 3 or less, low quality.
Data Analysis
We calculated the weighted mean difference (WMD) and appropriate 95% confidence intervals [CIs] using a random-effect model according to the number of patients based on intention-to-treat analysis when possible. The weight given to each study was equal to the inverse of the variance. In cases where studies did not report results based on intention-totreat, we analyzed outcomes based on the randomized population.
Potential publication bias was assessed with the Begg test and represented graphically with funnel Note: Patients' major condition: AS, atherosclerosis; CHD, coronary heart disease; DM, diabetes mellitus; HCho, hypercholesterolemia; HP, hypertension; CHD, coronary artery disease; PAD, peripheral arterial disease; (P), primary prevention; (S), secondary prevention. Design: DB, double blind; NR, not reported; TB, tri-blind; O, open; R, randomization without detailed information; BR, block randomization; MR, multi-centered randomization. Statin: L, Lovastatin; A, Atorvastatin; F, Fluvastatin; S, Simvastatin; P, Pravastatin; R, Rosuvastatin; C, cerivastatin; PLA, placebo; UC, usual care; anti-HP, anti-hypertension therapy;
Patients, T (I/C): T, Total; I: intervention; C: control; PMI, previous myocardial infarction; PDM, pervious diabetes mellitus; c-SMK, current smoking; BMI, body mass index. IMT as the outcome measure [35] [36] [37] ; (3) ARBITER, ASAP, Van, and VYCTOR compared different statins [19] [20] [21] [22] ; (4) Yu's trial compared different doses of the same statin 38) ; (5) Nakamura's trial had a followup of less than 6 months 39) ; and (6) Lorenzo's trial was still ongoing at the time of our analysis 40) . Twenty-one studies met the inclusion criteria and were thus included in this systematic review (Fig. 1) .
Study Characteristics
The 21 trials (investigating 7 different statins) had a sample size ranging from 36 to 984, and involved 6317 individuals 2-13, 17, 18, 41-47) . Twelve of the studies recruited participants with a previous history of cardiovascular disease or subclinical carotid atherosclerosis (AS). The remaining 9 studies recruited participants without an obvious diagnosis of carotid AS. The reported mean age of the participants ranged from 51 to 71 years old with the exception of Wiegman's study
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Results

Study Selection
A search of Medline, EMbase and Cochrane Central provided 229 citations. Of these, 181 trials did not meet all the inclusion criteria based on a review of the abstracts and were discarded. Another 14 trials were excluded after reviewing the full papers: (1) PLAS-Ⅱ, KAPS, PHYLLIS, and CAIUS did not provide enough data for meta-analysis 1, [32] [33] [34] ; (2) Watanabe, OSACA-2, and Yamada used integrated backscatter values or plaque thickness rather than CCA- This was consistent across both the low and high quality studies as identified by JADAD scoring. A significant decrease in mean CCA-IMT was observed in studies using statins for secondary prevention (WMD: −0.045; 95%CI: −0.046, −0.043), but not primary prevention (WMD: −0.004; 95%CI: −0.013, 0.006). The effect was also significant only after a duration of at least 2 or more years on statin therapy (WMD: −0.044; 95%CI: −0.045, −0.043). The effect was observed to be greater among a younger patient population than an older patient population (WMD: −0.057 vs. −0.041), and in trials where males outnumbered females (−0.044 vs. −0.008) ( Table 3) .
In an attempt to identify other sources of residual difference between trials, we performed metaregression analysis of baseline mean CCA-IMT and the net decrease (difference between decrease of intervention and control group) in lipid levels (TC, TG, LDL-C and HDL-C) (Fig. 4) . Of these variables, we found a significant association between decreases of mean CCA-IMT with net decrease in TG levels. A similar, but not statistically significant trend was also seen in mean CCA-IMT decrease and decrease in LDL-C levels and increase in HDL-C levels. No such association was found in regard to changes in TC levels.
Discussion
Summary of Evidence
Overall, statins can significantly reduce CCA-IMT compared to a placebo or usual care; however, (mean age 13 years old) 47) , and the proportion of males in the included studies ranged from 32% to 100% (Table 1) . CCA-IMT was measured with Bmode ultrasound in all included cases (for details refer to Appendix 2) and the mean CCA-IMT at baseline ranged from 0.495 mm to 1.525 mm ( Table 2) .
Syntheses of Results
We detected a significant weighted mean difference (WMD) in the decrease in mean CCA-IMT between statin therapy and placebo or usual care (WMD: −0.029; 95%CI: −0.045, −0.013). Strong evidence of heterogeneity (I 2 = 95.7%, p＜0.001) was observed (Fig. 2) . Sensitivity analyses excluding the trial evaluating the effect of cerivastatin resulted in a minor increase in the I 2 from 95.7% to 95.9%, but no change in the pooled WMD 46) . Another sensitivity analysis excluding Wiegman's trial resulted in a slight improvement in heterogeneity, but again no change in the pooled WMD 47) ; however, both the Begg test (p = 0.005) and funnel plots (Fig. 3) demonstrated a significant publication bias when looking at all 21 trials.
Additional Analyses
Subgroup analyses showed significant effects of lovastatin (WMD: −0.077; 95%CI: −0.082, −0.073) and simvastatin (WMD: −0.069; 95%CI: −0.094, −0.045) on the decrease of mean CCA-IMT, followed by pravastatin and rosuvastatin, but no significant benefits of atorvastatin, fluvastatin, or cerivastatin. showed that lowering serum cholesterol is effective in controlling the progression of CCA-IMT in a preventative setting and/or in patients whose presentation of atherosclerosis is still at an asymptomatic stage 32, 33) . Thirdly, we found a significant relationship between CCA-IMT decrease and the net decrease in TG (Fig. 5) . We also found a strong, although not statistically significant relationship between the magnitude of CCA-IMT decrease and the net decrease in LDL-C levels. The role of hypertriglyceridemia in the pathogenesis of atherosclerotic disease has been controversial for many years 48, 49) , despite extensive investigation by basic scientists, clinicians, and epidemiologists. Because triglycerides do not accumulate in the vessel wall, its atherogenicity is thought to be based on the association between triglycerides and cholesterol 50) . Because of the multiple links between elevated triglyceride levels and risk for atherosclerotic cardiovascular disease, it seems prudent to screen for the presence of hypertriglyceridemia when determining a patient's risk for atherosclerotic cardiovascular disease. A therapeutic program targeting a decrease of triglycerides is even more important in patients with hypertriglyceridemia than in persons with isolated hypercholesterolemia 50) . Fourthly, findings from CAIUS and ACAPS sugthis beneficial effect is not consistently seen in all statins, as insufficient evidence was found in the cases of atorvastatin, fluvastatin and cerivastatin. This is the first difference drawn from our systematic review compared with previous systematic reviews; however, further studies are needed to clarify the differential effects of statins on CCA-IMT.
Secondly, we found that the effect of lipid lowering on decreases in CCA-IMT was significant only in the setting of statin's use in secondary prevention, namely in the presence of carotid AS or more advanced arterial diseases such as coronary artery disease, but not in the setting of primary prevention. A possible explanation for this observation may be due to the larger IMT seen in more serious diseases, thus providing greater potential for decrease; however, this does not mean that statin therapy is unnecessary in the primary prevention of subclinical carotid AS. The lack of statin's beneficial effect in a primary prevention setting may be due to the small sample size, because the pooled WMD was still negative at −0.004, although statistically insignificant. An included trial that looked at statin therapy in the setting of primary prevention, FAST 6) , showed it to be effective in reducing CCA-IMT. Similar findings in CAIUS and KAPS 
Conclusions
Statins can significantly reduce the common carotid intima-media thickness when compared with a placebo or usual care, and this effect is mainly driven by baseline CCA-IMT and the extent of betweengroup lipid decrease. gested that there may be an "efficacy window", i.e., a carotid IMT range, during which progression may be slowed and/or stabilized, but above which lipid-lowering treatment is less effective 32, 51) . The results of our systematic review showed that lowering lipid levels can reduce atherosclerotic progression within a broad range of baseline IMT and cholesterol levels (results not shown). More interestingly, as baseline IMT increased, the decrease in CCA-IMT also increased. This finding further supports the use of lipid-lowering therapy in symptomatic or worse stages of AS, as lipid-lowering treatment may lead to greater stabilization in the progression of AS.
Risk of Bias Across Studies
Specifically, four trials, PLAS-Ⅱ, KAPS, PHYL-LIS and CAIUS, involving about 1400 participants, either did not report mean CCA-IMT or only reported the maximum IMT at the end of their studies 1, [32] [33] [34] . Undoubtedly, omission of these trials may be the source of the asymmetry seen in the funnel plot. The demographic characteristics of the participants, the duration of follow-up, and the type and dose of statin used can also lead to heterogeneity. Despite these potential biases, sensitivity analyses and subgroup analysis revealed nearly consistent results.
Limitations
The present study has some potential limitations that should be considered. First, a meta-analysis is retrospective research that is subject to the methodological deficiencies of the studies included, although we tried to minimize the likelihood of bias by developing a detailed protocol and using explicit criteria for study selection, data extraction, and analysis. Second, as in other meta-analyses, these results should be interpreted with caution, since individual studies varied considerably with respect to the demographic characteristics of the participants, the duration of follow-up, and the type and dose of statin used. The benefits of statin therapy on CCA-IMT depend on the baseline risk of the populations treated. In primary prevention trials, the benefits of statins remain unclear. Third, we had insufficient data to analyze the effects of statins on mean CCA-IMT in different subgroups (e.g., men and women). Such analyses are more informative when performed using individual participant data rather than cohort level data. Similar approaches are also needed to determine whether there is a significant correlation between decreasing LDL-C and decreases in mean CCA-IMT. Fourth, as shown in 
